Effect of aflatoxin B1 on nuclear receptors PXR, CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes

International Journal of Toxicology

Volumn 31, Issue 1, 2012, Pages 86-93

  Ayed Boussema, Imen ^a   Pascussi, Jean Marc ^b,c   Maurel, Patrick ^b   Bacha, Hassen ^a   Hassen, Wafa ^a  

^a Laboratory of Research on Biologically Compatible Compounds   (Tunisia)

^b INSERM   (France)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

aflatoxin B1; cytochromes P450; nuclear receptors; primary culture of human hepatocytes

Indexed keywords

AFLATOXIN B1; AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; PREGNANE X RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; MALE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AFLATOXIN B1; AGED; AGED, 80 AND OVER; CARCINOGENS; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER;

ANIMALIA;

EID: 84857615718     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811422453     Document Type: Article

References (58)

1. Guengerich FP. Molecular advances for the cytochrome P-450 superfamily. Trends Pharmacol Sci. 1991 ; 12 (8). 281-283
2. Mansuy D. The great diversity of reactions catalyzed by cytochromes P450. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 ; 121 (1-3). 5-1
3. Ioannides C, Lewis DF. Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem. 2004 ; 4 (16). 1767-1788 (Pubitemid 39662666)
4. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica. 2007 ; 37 (12). 1367-1377 (Pubitemid 350146687)
5. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008 ; 82 (10). 667-715
6. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008 ; 392 (6). 1093-1108
7. Dickins M. Induction of cytochromes P450. Curr Top Med Chem. 2004 ; 4 (16). 1745-1766 (Pubitemid 39654460)
8. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res. 2006 ; 23 (6). 1089-1116 (Pubitemid 43946134)
9. Ma Q. Xenobiotic-activated receptors: fromtranscription to drug metabolism to disease. Chem Res Toxicol. 2008 ; 21 (9). 1651-1671
10. Qatanani M, Moore DD. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab. 2005 ; 6 (4). 329-339 (Pubitemid 41086766)
11. Chang TKH. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006 ; 38: 51-73 (Pubitemid 43738999)
12. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol Pharmacol. 2006 ; 3: 231-251 (Pubitemid 44021431)
13. Okey AB, Bondy GP, Mason ME, Kahl GF, Eisen HJ, Guenthner TM. Regulatory gene product of the Ah locus. Characterization of the cytosolic inducer-receptor complex and evidence for its nuclear translocation. J Biol Chem. 1979 ; 254 (22). 11636-11648 (Pubitemid 10140087)
14. Poland A. Knutson JC. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol. 1982 ; 22: 517-554
15. Matsumoto Y, Ide F, Kishi R, et al. Aryl hydrocarbon receptor plays a significant role in mediating airborne particulate-induced carcinogenesis in mice. Environ Sci Technol. 2007 ; 41 (10). 3775-3780 (Pubitemid 350067228)
16. Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, Lee KS. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol. 2000 ; 57 (5). 1056-1063 (Pubitemid 30253392)
17. Bock KW, Kohle C. Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol. 2005 ; 69 (10). 1403-1408 (Pubitemid 40602440)
18. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem. 2005 ; 96 (6). 1174-1184 (Pubitemid 41681860)
19. Puga A, Tomlinson CR, Xia Y. Ah receptor signals cross-talk with multiple developmental pathways. Biochem Pharmacol. 2005 ; 69 (2). 199-207 (Pubitemid 41556566)
20. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002 ; 82: 1-556
21. Eaton DL, Ramsdell HS, Neal GE The Toxicology of Aflatoxins, Human Health, Veterinary and Agricultural Significance. Eaton DL Groopman JD, ed. San Diego, CA: Academic Press ; 1994: 45-72.
22. Denissenko MF, Cahill J, Koudriakova TB, Gerber N, Pfeifer GP. Quantitation and mapping of aflatoxin B1-induced DNA damage in genomic DNA using aflatoxin B1-8,9-epoxide and microsomal activation systems. Mutat Res. 1999 ; 425 (2). 205-211 (Pubitemid 29182654)
23. Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM. The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2002 ; 99 (10). 6655-6660 (Pubitemid 34526188)
24. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis. Carcinogenesis. 2001 ; 22 (4). 535-545 (Pubitemid 32288652)
25. Scholl PF, Musse SM, Groopman JD. Synthesis and characterization of aflatoxin B1 mercapturic acids and their identification in rat urine. Chem Res Toxicol. 1997 ; 10 (10). 1144-1151 (Pubitemid 27449518)
26. Ueng Y, Shimada T, Yamazaki H, Guengerich F. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol. 1995 ; 8 (2). 218-225
27. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langou S. Activation and detoxication of aflatoxin B1. Mutat Res. 1998 ; 402 (1-2). 121-128
28. Guillouzo A, Morel F, Fardel O, Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology. 1993 ; 82 (1-3). 209-219
29. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci. 2001 ; 13 (4). 343-368
30. Pichard-Garcia L, Gerbal-Chaloin S, Ferrini JB, Fabre JM, Maurel P. Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. Methods Enzymol. 2002 ; 357: 311-321 (Pubitemid 35231367)
31. Isom HC, Secott T, Georgoff I, Woodworth C, Mummaw J. Maintenance of differentiated rat hepatocytes in primary culture. Proc Natl Acad Sci U S A. 1985 ; 82 (10). 3252-3256 (Pubitemid 15033161)
32. Garner RC, Miller EC, Miller JA. Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res. 1972 ; 32 (10). 2058-2066
33. Gallagher EP, Kunze KL, Stapleton PL, Eaton DL. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol. 1996 ; 141 (12). 595-606 (Pubitemid 27046386)
34. Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci U S A. 1989 ; 86 (2). 462-465 (Pubitemid 19037765)
35. Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 1994 ; 54 (1). 101-108 (Pubitemid 24042095)
36. Kamdem LK, Meineke I, Godtel-Armbrust U, Brockmoller J, Wojnowski L. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol. 2006 ; 19 (4). 577-586
37. Tang C, Lin JH, Lu AYH. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?. Drug Metab Dispos. 2005 ; 33 (5). 603-613 (Pubitemid 40593872)
38. Martin H, Sarsat JP, De Waziers I, Housset C, Balladur P, Beaune P, et al. Induction of cytochrome P450 2B6 and 3A4 expression by Phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003 ; 20 (4). 557-568 (Pubitemid 36438898)
39. Persson KP, Ekehed S, Otter C, Lutz ES, Mcpheat J, Masimirembwa CM, et al. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res. 2006 ; 23 (1). 56-69 (Pubitemid 43214661)
40. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 ; 29 (3). 242-251 (Pubitemid 32179522)
41. Kim J, Min G, Kemper B. Chromatin assembly enhances binding to the CYP2B1 Phenobarbital-responsive unit (PBRU) of nuclear factor-1, which binds simultaneously with constitutive androstane receptor (CAR)/retinoid X receptor (RXR) and enhances CAR/RXR-mediated activation of the PBRU. J Biol Chem. 2001 ; 276 (10). 7559-7567
42. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem. 2000 ; 275 (20). 15122-15127 (Pubitemid 30337234)
43. Honkakoski P, Zelko I, Sueyoshi T, Negishi M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the Phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol. 1998 ; 18 (10). 5652-5658 (Pubitemid 28450516)
44. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998 ; 92 (1). 73-82 (Pubitemid 28053299)
45. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation ox xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 2000 ; 14 (23). 31014-31023
46. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol. 1999 ; 19 (9). 6318-6322 (Pubitemid 29399336)
47. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by Rifampicin through a distal enhancer module. Mol Pharmacol. 1999 ; 56 (6). 1329-1339
48. Frank C, Makkonen H, Dunlop TW, Matilainen M, Väisänen S, Carlberg C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J Mol Biol. 2005 ; 346 (2). 505-519
49. Goodwin B, Moore JT. CAR: detailing new models. Trends Pharmacol Sci. 2004 ; 25 (8). 437-441 (Pubitemid 38981560)
50. Yoshinari K, Tien E, Negishi M, Honkakoski P Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and Other Xenobiotics. Ioannides C, ed. Cambridge: RSC ; 2008: 417-448.
51. Tan Z, Huang M, Puga A, Xia Y. A critical role for MAP kinases in the control of Ah receptor complex activity. Toxicol Sci. 2004 ; 82 (1). 80-87 (Pubitemid 39485322)
52. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. 2007 ; 581 (19). 3608-3615
53. Chang CY, Puga A. Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol. 1998 ; 18 (1). 525-535 (Pubitemid 28021063)
54. Klein PJ, Van Vleet TR, Hall JO, Coulombe RA. Dietary butylated hydroxytoluene protects against aflatoxicosis in turkeys. Toxicol Appl Pharmacol. 2002 ; 182 (1). 11-19 (Pubitemid 34775472)
55. Guarisco JA, Hall JO, Coulombe RA. Butylated hydroxytoluene chemoprevention of aflatoxicosis-effects on aflatoxin B1 bioavailability, hepatic DNA adduct formation, and biliary excretion. Food Chem Toxicol. 2008 ; 46 (12). 3727-3731
56. Gross-Steinmeyer K, Stapleton PL, Tracy JH, Bammler TK, Strom SC, Eaton DL. Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol Sci. 2010 ; 116 (2). 422-432
57. Langouet S, Coles B, Morel F, et al. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res. 1995 ; 55 (23). 5574-5579
58. Bruno RD, Njar VCO. Targeting cytochromes P450 enzymes: A new approach in anticancer drug development. Bioorg Med Chem. 2007 ; 15 (15). 5047-5060 (Pubitemid 46880385)